Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
Julie R Park, David L Digiusto, Marilyn Slovak...
https://pubmed.ncbi.nlm.nih.gov/17299405/Actively Recruiting
Led by Institute of Hematology and Blood Transfusion, Czech Republic · Updated on 2025-01-06
10
Participants Needed
1
Research Sites
27 weeks
Total Duration
Researchers are evaluating the safety and appropriate dosing of CART19 cells in adult patients with relapsed or refractory CD19-positive B-cell Acute Lymphoblastic Leukemia B-ALL or Non-Hodgkins Lymphoma NHL. This Phase I, open-label, single-arm study aims to find the maximum tolerated or feasible dose of these engineered T cells, which are designed to target cancer cells. Up to 24 adults with these conditions will participate to understand the treatments effects and potential risks. Participants will first undergo a lymphodepleting conditioning regimen to prepare their immune system. They will then receive a single dose of autologous CAR19 T lymphocytes, which are made from their own cells and modified to recognize CD19 on cancer cells. The dose of CART19 will be increased stepwise in consecutive patients to establish the recommended dose for future studies. This dosing approach continues until either the maximum tolerated dose or maximum feasible dose is identified. During the study, patients will be closely monitored for adverse events and dose-limiting toxicities up to 28 days after receiving the treatment and for up to two years thereafter. Researchers will also assess complete remission rates at 100 days and 6 months, overall survival at one year, and quality of life using a cancer-specific questionnaire at 6 months and one year. The study includes extensive evaluations, including imaging, laboratory tests, and quality-of-life assessments to track the patients status throughout the trial and follow-up period.
CONDITIONS
CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
J
Jan Vydra
P
Petr Lesny
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Institute of Hematology and Blood Transfusion, Czech Republic
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 28 days after treatment administration
Participants receive a lymphodepleting conditioning regimen followed by a single dose of autologous CAR19 T lymphocytes to evaluate safety and efficacy.
1 treatment visit and several visits during 28 days post-treatment
Duration - Up to 2 years post treatment
Participants are monitored for safety, remission status, overall survival, and quality of life up to 2 years after treatment.
Visits at 100 days, 6 months, 1 year, and up to 2 years following treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Julie R Park, David L Digiusto, Marilyn Slovak...
https://pubmed.ncbi.nlm.nih.gov/17299405/Michael C Milone, Vijay G Bhoj
https://pubmed.ncbi.nlm.nih.gov/29552577/Daniel W Lee, Bianca D Santomasso, Frederick L Locke...
https://pubmed.ncbi.nlm.nih.gov/30592986/Perry B Hackett, David A Largaespada, Kirsten C Switzer...
https://pubmed.ncbi.nlm.nih.gov/23313630/Salima Hacein-Bey-Abina, Christof von Kalle, Manfred Schmidt...
https://pubmed.ncbi.nlm.nih.gov/12529469/Richard J Powell, Michael Simons, Farrel O Mendelsohn...
https://pubmed.ncbi.nlm.nih.gov/18559703/Jaitip Tipanee, Thierry VandenDriessche, Marinee K Chuah
https://pubmed.ncbi.nlm.nih.gov/28920716/Gianpietro Dotti
https://pubmed.ncbi.nlm.nih.gov/23728254/Brian G Till, Michael C Jensen, Jinjuan Wang...
https://pubmed.ncbi.nlm.nih.gov/18509084/James N Kochenderfer, Mark E Dudley, Sadik H Kassim...
https://pubmed.ncbi.nlm.nih.gov/25154820/Institute of Hematology and Blood Transfusion, Czech Republic
Lead Sponsor